Table 3.

Base case results for CVD risk without and with diabetes for four risk levels. All dominated strategies have been excluded

CVD risk
Strategy	Cost	IC	Eff	IE	ICER	Strategy	Cost	IC	Eff	IE	ICER
Low risk						Moderate risk
No treatment	461		0.00			No treatment	1516		0.00
ACEI_Diu	1005	544	0.41	0.41	1327	ACEI_Diu	1683	167	1.02	1.02	164
ACEI_Diu_Sta	1259	254	0.49	0.08	3175	ACEI_Diu_Sta	1827	144	1.28	0.26	554
High risk						Very high risk
No treatment	1695		0.00			No treatment	2028		0.00
ACEI_CCB_Diu	2240	545	1.56	1.56	349	ACEI_CCB_Diu_ASA	3244	1216	2.44	2.44	498
ACEI_CCB_Diu_Sta	2404	164	1.83	0.27	607	ACEI_CCB_Diu_Sta_ASA	3433	189	2.73	0.29	652
CVD risk with diabetes
Strategy	Cost	IC	Eff	IE	ICER	Strategy	Cost	IC	Eff	IE	ICER
Low risk						Moderate risk
No treatment	964		0.00			No treatment	1805		0.00
Sulf_ACEI_CCB	1481	517	0.85	0.85	608	Sulf_ACEI_CCB	1966	161	1.40	1.40	115
Big_Sulf_ACEI_CCB	1778	297	1.16	0.31	958	Big_Sulf_ACEI_CCB	2122	156	2.01	0.61	256
Big_Sulf_ACEI_CCB_Sta	2026	248	1.26	0.10	2480	Big_Sulf_ACEI_CCB_Sta	2311	189	2.21	0.20	945
High risk						Very high risk
No treatment	1909		0.00			No treatment	2514		0.00
Big_Sulf_ACEI_CCB	2576	667	2.16	2.16	309	Big_Sulf_ACEI_CCB_ASA	3696	1182	3.38	3.38	350
Big_Sulf_ACEI_CCB_Sta	2768	192	2.37	0.21	914	Big_Sulf_ACEI_CCB_Sta_ASA	3893	197	3.66	0.28	704
Big_Sulf_ACEI_ARB_CCB_Sta	3798	1030	2.47	0.10	10300	Big_Sulf_ACEI_ARB_CCB_Sta_ASA	4883	990	3.79	0.13	7615

IC Incremental cost, Eff Effectiveness, IE Incremental effectiveness, ICER Incremental cost-effectiveness ratio